Das Thakur, M and Stuart, DD (2014) Molecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAF(V600E) Tumors. CLINICAL CANCER RESEARCH. pp. 1074-1080.

Abstract

The RAS-RAF-MEK (MAP-ERK kinase)-ERK (extracellular signal-regulated kinase) pathway plays a central role in driving proliferation, survival, and metastasis signals in tumor cells, and the prevalence of oncogenic mutations in RAS and BRAF and upstream nodes makes this pathway the focus of significant oncology drug development efforts. This focus has been justified by the recent success of BRAF and MEK inhibitors in prolonging the lives of patients with BRAF V600E/K -mutant melanoma. Although it is disappointing that cures are relatively rare, this should not detract from the value of these agents to patients with cancer and the opportunity they provide in allowing us to gain a deeper understanding of drug response and resistance. These insights have already provided the basis for the evaluation of alternative dosing regimens and combination therapies in patients with melanoma. (C) 2013 AACR

Item Type:	Article
Additional Information:	NIBR author: Stuart DD; institute: NIBR contributor address: Novartis Inst Biomed Res, Emeryville, CA 94608 USA darrin.stuart@novartis.com; Novartis Inst Biomed Res, Emeryville, CA 94608 USA; Stuart, D D; Novartis Inst Biomed Res, 4560 Horton St MS 4-3, Emeryville, CA 94608 USA
Date Deposited:	13 Oct 2015 13:12
Last Modified:	13 Oct 2015 13:12
URI:	https://oak.novartis.com/id/eprint/22590